Systematic Review of Safety and Efficacy of COVID-19 Vaccines in Patients With Kidney Disease

Glenn, Dorey; Hegde, Anisha; Kotzen, Elizabeth S.; Walter, Emmanuel B.; Kshirsagar, Abhijit V.; Falk, Ronald J.; Mottl, Amy K.

doi:10.1016/j.ekir.2021.02.011

Cited by 67 publications

(53 citation statements)

References 8 publications

(1 reference statement)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Pivotal studies using lipid nanoparticle-encapsulated mRNA-based vaccines that encodes the full-length spike protein of SARS-CoV-2, indeed shown excellent efficacy (95%) at preventing COVID-19 illness in the general population after two doses of the vaccine administered intramuscularly three weeks apart 13,14 . However, whether these good results are generalizable to individuals living with kidney disease, in particular those on MHD, is not certain because the latter were not enrolled in these studies 15 . Furthermore, several lines of evidence suggest that in MHD patients, immune response (in particular after vaccination) may be blunted 7,8 .…”

Section: Title Page [Query To Author: Title and Abstract Rewritten By Editorial Officenot Subject To Change]mentioning

confidence: 99%

The ROMANOV study found impaired humoral and cellular immune responses to SARS-CoV-2 mRNA vaccine in virus-unexposed patients receiving maintenance hemodialysis

Espi

Charmetant

Barba

et al. 2021

Kidney International

View full text Add to dashboard Cite

show abstract

Section: Title Page [Query To Author: Title and Abstract Rewritten By Editorial Officenot Subject To Change]mentioning

confidence: 99%

The ROMANOV study found impaired humoral and cellular immune responses to SARS-CoV-2 mRNA vaccine in virus-unexposed patients receiving maintenance hemodialysis

Espi

Charmetant

Barba

et al. 2021

Kidney International

View full text Add to dashboard Cite

show abstract

“…Early and rapid vaccination is an absolute priority for this at-risk group, but while the results of vaccine trials have been impressive in the general population, the effectiveness of these vaccines have not been explicitly tested in patients with CKD who are often excluded from the trials (see Table 1 ) [ 3 ]. At this time clinical vaccine efficacy, immunogenicity and persistence of protection are known-unknowns in the patients with CKD (including transplant recipients) and patients with End Stage Kidney Disease (ESKD) [ 4 ] [ 5 ]. Understanding the response to vaccination in patients with CKD is a top priority for researchers and healthcare professionals who look after people with kidney disease.…”

Section: Introductionmentioning

confidence: 99%

Review of Early Immune Response to SARS-CoV-2 Vaccination Among Patients With CKD

Carr

Kronbichler

Graham-Brown

et al. 2021

Kidney International Reports

107

108

View full text Add to dashboard Cite

Introduction The effects of the coronavirus disease 19 (COVID-19) pandemic in particular affect those with chronic kidney disease (CKD), who commonly have defects in humoral and cellular immunity, and the efficacy of vaccinations against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is uncertain. Methods To inform public health and clinical practice, we synthesized published studies and preprints evaluating surrogate measures of immunity after SARS-CoV-2 vaccination in patients with CKD including those receiving dialysis or with a kidney transplant. Results We found 35 studies (28 published, 7 preprints), sample size from 23 to 1140 patients, and follow-up from one week to 1 month after vaccination. 17 of the 35 studies enrolled a control group. In the 22 studies of patients receiving dialysis, the development of antibodies was observed in 18 to 53% after one dose, and in 70 to 96% after two doses of mRNA vaccine. In the 14 studies of transplant recipients, 3% to 59% mounted detectable humoral or cellular responses after 2 doses of mRNA vaccine. After vaccination, there are a few reported cases of relapse or de novo glomerulonephritis, and acute transplant rejection suggesting ongoing surveillance is important. Conclusion Studies are needed to better evaluate the effectiveness of SARS-CoV-2 vaccination in these populations. Rigorous surveillance for long-term adverse effects in patients with autoimmune disease and transplant recipients is required. For transplant recipients and those with suboptimal immune responses, alternate vaccination platforms and strategies should be considered. As additional data arise, the NephJC COVID-19 page will be updated ( http://www.nephjc.com/news/covid-vaccine ).

show abstract

“…However, the absolute incidence was low, with 10 reports of de novo or relapsed IgAN, including 1 from our institution 2 . Vaccine safety data in IgAN are lacking in part because immunosuppressed patients, including those with glomerular diseases, were generally excluded 3…”

Section: Covid-19 Vaccination In Immunoglobulin a Nephropathymentioning

confidence: 99%

COVID-19 Vaccination in Immunoglobulin A Nephropathy

Lim

Choo

Tan

2021

American Journal of Kidney Diseases

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

Systematic Review of Safety and Efficacy of COVID-19 Vaccines in Patients With Kidney Disease

Cited by 67 publications

References 8 publications

The ROMANOV study found impaired humoral and cellular immune responses to SARS-CoV-2 mRNA vaccine in virus-unexposed patients receiving maintenance hemodialysis

The ROMANOV study found impaired humoral and cellular immune responses to SARS-CoV-2 mRNA vaccine in virus-unexposed patients receiving maintenance hemodialysis

Review of Early Immune Response to SARS-CoV-2 Vaccination Among Patients With CKD

COVID-19 Vaccination in Immunoglobulin A Nephropathy

Contact Info

Product

Resources

About